RH43 Antibody
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Q&A
Here’s a structured collection of FAQs for researchers studying RH43 antibodies, synthesized from peer-reviewed studies and technical reports:
What is the RH43 (Crawford) antigen, and how does it differ from other Rh system antigens?
RH43 is a high-prevalence antigen in the Rh blood group system encoded by the RHCEceCF* allele. This variant carries three nucleotide changes (48G>C, 697C>G, 733C>G), leading to amino acid substitutions (Trp16Cys, Gln233Glu, Leu245Val) that alter c/e antigen expression and abolish CELO (RH58), a high-prevalence antigen antithetical to RH43 . Unlike conventional Rh antigens, RH43-positive RBCs show:
-
Partial c/e antigen expression (reduced reactivity with monoclonal anti-e MS16/MS69) .
-
Absence of CELO, detectable via adsorption-elution studies with anti-CELO sera .
Methodological Tip: Confirm RH43 status using RHCE sequencing, AS-PCR for 48G>C/697C>G/733C>G variants, and hemagglutination with anti-CELO .
How do RH43 antibodies impact transfusion medicine?
RH43 antibodies are clinically significant due to their association with:
-
Hemolytic transfusion reactions: Anti-RH43 can react with >99.9% of donor RBCs lacking RH43 .
-
Partial antigen challenges: Weak c/e expression on RH43+ RBCs complicates serologic typing; use monoclonal/polyclonal reagent blends for resolution .
Experimental Design: Screen patient sera against RH43-negative (e.g., Rh null, D--, or RHCEceBP* RBCs) and RH43+ panels to distinguish anti-RH43 from anti-CELO .
How can researchers resolve discrepancies in RH43 antibody identification?
Conflicting serologic results often arise from:
-
Cross-reactivity: Anti-RH43 may mimic anti-c/e if partial antigens are unrecognized.
-
High-prevalence antigen interference: Use adsorption with CELO+ RBCs to isolate anti-RH43 .
Data Contradiction Analysis:
| Scenario | Solution |
|---|---|
| Anti-RH43 misidentified as anti-c/e | Retest with RH43+ (CELO–) and RH43– (CELO+) RBCs |
| Weak reactivity with commercial anti-e | Employ monoclonal anti-e blends (e.g., MS16 + MS21) |
What strategies validate RH43 antigen expression in novel alleles?
A multi-modal approach is critical:
-
Molecular analysis: Sanger sequencing of RHCE exons 1–7 for 48G>C/697C>G/733C>G .
-
Flow cytometry: Quantify c/e density using fluorophore-conjugated monoclonal antibodies (e.g., anti-e FITC) .
-
Functional assays: Measure antibody-mediated phagocytosis of RH43+ RBCs in macrophage models .
Validation Note: Correlate genomic findings with serologic phenotypes to avoid false positives .
How can RH43 research inform broader Rh system studies?
RH43’s partial c/e expression and CELO absence provide a model for:
-
Antigen topology: Mapping conformational epitopes via site-directed mutagenesis of RHCEceCF* .
-
Antibody evasion: Study RH43+ RBC survival in autoimmune hemolytic anemia models .
Cross-Disciplinary Approach: Combine cryo-EM (to visualize RhCE structure) with mass cytometry (to profile antibody binding kinetics) .
